Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
3(60.0%)
Phase 2
1(20.0%)
Phase 3
1(20.0%)
5Total
N/A(3)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04539951Phase 2Recruiting

Pragmatic Trial of Obsessive-compulsive Disorder

Role: collaborator

NCT04853485Not ApplicableUnknown

Repetitive Transcranial Magnetic Stimulation in Early Psychosis and The Functional Connectivity Biotypes

Role: collaborator

NCT03932136Phase 3Recruiting

Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)

Role: collaborator

NCT03497013Not ApplicableCompleted

Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia

Role: lead

NCT03273439Not ApplicableCompleted

A Study of rTMS for Cognitive Deficits in Chronic Patients With Schizophrenia

Role: lead

All 5 trials loaded